Prosecution Insights
Last updated: April 19, 2026
Application No. 18/447,057

METHOD AGAINST SNAKE ENVENOMATION

Non-Final OA §102
Filed
Aug 09, 2023
Examiner
ROZOF, TIMOTHY R
Art Unit
1625
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
National Tsing Hua University
OA Round
1 (Non-Final)
73%
Grant Probability
Favorable
1-2
OA Rounds
2y 2m
To Grant
97%
With Interview

Examiner Intelligence

Grants 73% — above average
73%
Career Allow Rate
690 granted / 951 resolved
+12.6% vs TC avg
Strong +24% interview lift
Without
With
+24.0%
Interview Lift
resolved cases with interview
Fast prosecutor
2y 2m
Avg Prosecution
32 currently pending
Career history
983
Total Applications
across all art units

Statute-Specific Performance

§101
1.6%
-38.4% vs TC avg
§103
20.1%
-19.9% vs TC avg
§102
34.4%
-5.6% vs TC avg
§112
23.5%
-16.5% vs TC avg
Black line = Tech Center average estimate • Based on career data from 951 resolved cases

Office Action

§102
Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . DETAILED ACTION This is a response to Applicant’s communication filed on August 9, 2023. Application No. 18/447,057, is a U.S. Nonprovisional application filed August 9, 2023, and claim the on benefit of U.S. Provisional application No. 63/397,147, filed August 11, 2022. Claims 1-8 are pending. Claim Rejections - 35 USC § 102(a)(1) The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action: A person shall be entitled to a patent unless – (a)(1) the claimed invention was patented, described in a printed publication, or in public use, on sale, or otherwise available to the public before the effective filing date of the claimed invention. Claims 1-8 are rejected under 35 U.S.C. 102(a)(1) as being anticipated by Singh et al., A Review on Venom Enzymes Neutralizing Ability of Secondary Metabolites from Medicinal Plants, 20(3) J. Pharmacopuncture 173-178 (2017). Singh discloses a method against snake envenomation of a neurotoxic venom (from Naja spp., i.e., Naja naja), comprising administering to a subject in need thereof a composition containing a flavonoid compound of at least quercetin. See Singh et al., p. 175, section “5. Flavanoids”. Conclusion No claims are allowed. Contact Information Any inquiry concerning this communication or earlier communications from the examiner should be directed to TIMOTHY R ROZOF whose telephone number is (571)270-5992. The examiner can normally be reached Monday - Friday, 9:00 a.m. -5:00 p.m.. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Andrew Kosar can be reached at (571) 272-0913. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /TIMOTHY R ROZOF/Primary Examiner, Art Unit 1625
Read full office action

Prosecution Timeline

Aug 09, 2023
Application Filed
Mar 16, 2026
Non-Final Rejection — §102 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12594259
TREATMENT REGIMEN FOR THE TREATMENT OF NEUROLOGICAL DISEASES OR CONDITIONS
2y 5m to grant Granted Apr 07, 2026
Patent 12595264
HETEROCYCLIC GLP-1 AGONISTS
2y 5m to grant Granted Apr 07, 2026
Patent 12595255
HETEROARYL-SUBSTITUTED IMIDAZOLE DERIVATIVES
2y 5m to grant Granted Apr 07, 2026
Patent 12577204
A SOLUTION OF TEMPO-DERIVATIVES FOR USE AS ELECTROLYTE IN REDOX-FLOW CELLS
2y 5m to grant Granted Mar 17, 2026
Patent 12577205
HYDROGENATION OF IMINES BY PALLADIUM BASED CATALYST
2y 5m to grant Granted Mar 17, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

AI Strategy Recommendation

Get an AI-powered prosecution strategy using examiner precedents, rejection analysis, and claim mapping.
Powered by AI — typically takes 5-10 seconds

Prosecution Projections

1-2
Expected OA Rounds
73%
Grant Probability
97%
With Interview (+24.0%)
2y 2m
Median Time to Grant
Low
PTA Risk
Based on 951 resolved cases by this examiner. Grant probability derived from career allow rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month